Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Jul-17

AUTHORS : Dr Mikhail Kosiborod, Saint Luke’s Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111 – E-mail: mkosiborod@saint-lukes.org – Profile: https://doctors.saintlukeskc.org/provider/Mikhail+N+Kosiborod/1458591 also read article: https://www.saintlukeskc.org/about/news/saint-lukes-innovation-week-profile-dr-mikhail-kosiborod

JOURNAL : Circulation

REFERENCE: 136(3):249-259

DOI : 10.1161/CIRCULATIONAHA.117.029190

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study